REGENXBIO Reports First Quarter 2022 Financial Results and R

/PRNewswire/ -- Continues to advance RGX-314 program for the treatment of wet AMD and diabetic retinopathy; remains on track for first BLA filing in 2024...

Related Keywords

Dana Cormack , Chris Brinzey , Technology Platform , Technology Platform Licensees , Trustees Of The University Pennsylvania , Nasdaq , Novartis , Technology Licensee Program , Development Expenses , Exchange Commission , Corporate Communications , Securities Exchange , Fortis , Chief Executive Officer , Biologics Licensing Application , Duchenne Muscular Dystrophy , Mucopolysaccharidosis Type , Hunter Syndrome , Good Manufacturing Practice , Licensee Program , Late Onset Pompe , Administrative Expenses , Platform Licensees , Securities Act , Securities Exchange Act , Financial Condition , Months Ended March , Tax Benefit , Regenxbio Inc ,